Which effect is NOT expected from the administration of Neostigmine?

The correct answer is that decreased gastric motility is not expected from the administration of Neostigmine. Neostigmine is a reversible acetylcholinesterase inhibitor that enhances the action of acetylcholine at the neuromuscular junction and autonomic nervous system synapses.

Typically, Neostigmine increases gastric motility by promoting the activity of the parasympathetic nervous system, which is involved in digestive processes. It stimulates the gastrointestinal tract, leading to increased peristalsis and secretion of digestive juices. Therefore, rather than decreasing gastric motility, Neostigmine is more likely to result in enhanced movement within the digestive system.

In contrast, miosis, which is the constriction of the pupils, increased secretions (such as saliva and gastric juices), and AV conduction delay may occur as a result of Neostigmine administration. Miosis results from enhanced cholinergic activity affecting the muscles controlling pupil size. Increased secretions are due to enhanced parasympathetic activity promoting glandular secretions. As for AV conduction delay, it can occur due to increased vagal tone associated with the augmented activity of acetylcholine in the heart.

Thus, the role of Neostigmine is primarily to